The gastrointestinal mucosal barrier is the first line of defense in the functional medicine approach to digestive health. Factors such as stomach acid (pH 1.5-3.5), digestive enzymes, medications (NSAIDs), Helicobacter pylori (H. pylori), and alcohol can damage the gastric mucosa, leading to gastritis, gastric ulcers, and increased intestinal permeability.
Zinc Carnosine (also known as Polaprezinc) is a chelate of zinc and L-carnosine developed by Hamol Co., Ltd. in Japan. It was approved as a prescription drug in 1994 under the brand name Promac for treating gastric ulcers and gastritis. Its key advantage lies in its "targeted delivery" mechanism: the chelated form keeps zinc stable in the acidic stomach environment, releasing zinc ions and carnosine slowly once it reaches the gastric mucosa.
Zinc carnosine protects the gastric mucosa through multiple mechanisms: direct adhesion to damaged mucosal surfaces (forming a protective barrier), stimulation of prostaglandin E2 synthesis (increasing mucosal blood flow), upregulation of heat shock protein HSP70 expression (cellular protection), inhibition of Helicobacter pylori growth, and activation of epidermal growth factor (EGF) signaling pathways (mucosal repair).
Multiple randomized controlled trials show that zinc carnosine (75 mg × 2 times/day) is as effective as H2 receptor antagonists (famotidine) in healing gastric ulcers and superior in preventing NSAID-induced gastric mucosal injury. Zinc carnosine has a favorable safety profile, with an adverse event rate below 5%.
In functional medicine product development, zinc carnosine is a key ingredient in the GI Support Series' gut mucosal repair formula (L-glutamine + zinc carnosine + MSM + aloe vera extract). Dynas Group Ltd. (Hong Kong) supports custom powder and capsule formulations, providing professional contract manufacturing solutions for gastrointestinal health brands backed by clinical evidence.
